(COV) Covivio - Ratings and Ratios
Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0000064578
COV: Offices, Hotels, Homes, Buildings, Spaces, Cities
Covivio SA (PA:COV) is a European real estate leader with a rich history of collaboration and a deep understanding of the evolving needs of cities and their inhabitants. The company specializes in creating spaces that blend work, travel, and living, leveraging its expertise to co-create vibrant, functional environments. With €23.1 billion in assets under management, Covivio has established itself as a key player in the European real estate market, supporting businesses, hospitality brands, and local authorities in their efforts to enhance attractiveness, drive transformation, and deliver sustainable performance.
At the heart of Covivios strategy is its commitment to fostering sustainable relationships and well-being. This purpose-driven approach reflects its role as a responsible real estate operator, addressing the needs of a broad range of stakeholders, including customers, shareholders, financial partners, local communities, and future generations. The companys dynamic and forward-thinking mindset also creates opportunities for innovation and growth within its teams, making it an attractive destination for talent in the industry.
Covivios shares are listed on Euronext Paris (Compartment A) under the ticker symbol COV (FR0000064578). They are included in several prominent indices, such as the MSCI, SBF 120, Euronext IEIF SIIC France, and CAC Mid100, as well as key ESG-focused indices like the FTSE4Good, DJSI World & Europe, and Euronext Vigeo. The company has also earned top ratings from leading ESG assessment firms, including CDP (A), GRESB (90/100, 5-Star), and Vigeo-Eiris (A1+), demonstrating its strong commitment to environmental, social, and governance practices.
Financially, Covivios market capitalization stands at €5,683.53 million, with a forward P/E ratio of 11.75 and a P/B ratio of 0.69. The companys P/S ratio is 5.35, reflecting its revenue generation capabilities. These metrics provide investors with a clear view of Covivios valuation and operational efficiency, making it a closely watched name in the European real estate sector.
For more information, visit Covivios official website: https://covivio.eu/en/.
Additional Sources for COV Stock
COV Stock Overview
Market Cap in USD | 6,165m |
Sector | Real Estate |
Industry | REIT - Diversified |
GiC Sub-Industry | Diversified REITs |
IPO / Inception |
COV Stock Ratings
Growth 5y | -1.65% |
Fundamental | -6.74% |
Dividend | 44.1% |
Rel. Strength | 2.44 |
Analysts | - |
Fair Price Momentum | 53.21 EUR |
Fair Price DCF | 132.09 EUR |
COV Dividends
Dividend Yield 12m | 13.87% |
Yield on Cost 5y | 14.56% |
Annual Growth 5y | -7.22% |
Payout Consistency | 91.7% |
COV Growth Ratios
Growth Correlation 3m | 51.5% |
Growth Correlation 12m | 49.5% |
Growth Correlation 5y | -41.7% |
CAGR 5y | 0.60% |
CAGR/Max DD 5y | 0.01 |
Sharpe Ratio 12m | 0.25 |
Alpha | 14.86 |
Beta | 1.665 |
Volatility | 23.85% |
Current Volume | 193.6k |
Average Volume 20d | 117.8k |
As of April 05, 2025, the stock is trading at EUR 48.14 with a total of 193,608 shares traded.
Over the past week, the price has changed by -7.42%, over one month by -7.24%, over three months by -2.07% and over the past year by +8.30%.
Neither. Based on ValueRay Fundamental Analyses, Covivio is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -6.74 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COV as of April 2025 is 53.21. This means that COV is currently undervalued and has a potential upside of +10.53% (Margin of Safety).
Covivio has no consensus analysts rating.
According to ValueRays Forecast Model, COV Covivio will be worth about 57.5 in April 2026. The stock is currently trading at 48.14. This means that the stock has a potential upside of +19.38%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 61.8 | 28.5% |
Analysts Target Price | - | - |
ValueRay Target Price | 57.5 | 19.4% |